Pfizer acquires biopharmaceutical company Global Blood Therapeutics (GBT)
Pfizer agreed to buy biopharmaceutical company Global Blood Therapeutics (GBT) for $5.4 billion. The acquisition of GBT will strengthen Pfizer's rare disease business and help it achieve its long-term goal of selling a treatment for sickle cell disease, Pfizer said.
2026-09-27
Trade Alert
Delivering the latest product trends and industry news straight to your inbox.
(We'll never share your email address with a third-party.)
Related News
-
How Can Investors Benefit from Pfizer's Dividend Yield for a Monthly Income?
-
Pfizer's Revenue Forecast Disappoints, Stock Plummets: A Closer Look at the Challenges Ahead
-
Pfizer's Angela Hwang Departs as Company Completes Seagen Acquisition and Establishes New Oncology Division
-
2023 Senior Management Personnel Changes of Multinational Pharmaceutical Companies in China, what's behind it? - III
-
Milestone Approvals in Sickle Cell Disease (SCD): FDA Approves Two Therapies before Pfizer's GBT601 Disclosure
-
Pfizer's Strategic Shift in China's Pneumococcal Vaccine Market
-
Pfizer Receives Conditional Approval for Tislelizumab in the Treatment of Relapsed or Refractory Extranodal NK/T-cell Lymphoma (ENKTL)
-
Pfizer: In 2023, COVID-19's product revenue will decline significantly
-
Pfizer's paxlovid reduces the risk of COVID-19 by 26%
-
The battle between Pfizer and Gilead over COVID-19 drugs will continue
Recommend Reading
-
Lilly’s Indiana Investment Puts API Capacity at the Center of Obesity Drug Competition
-
ExxonMobil Shuts Another Singapore Facility: The Global Petrochemical Shake-Up Leaves No Easy Winners
-
One Ton of Fake Plastic Nearly Burned China’s Manufacturing Reputation—Wanhua Chemical Exposes the Underbelly of the Chemical Black Market
-
Sinopec and CNAF to Implement Restructuring
-
Korea’s Antitrust Probe Targets Coatings Price Hikes as Five Major Players Come Under Investigation
-
Formic Acid Market Supply Is Loose, Inventory Reduction Is Orderly
-
Optimistic Expectations for US-Iran Talks Lead to Sharp Drop in Oil Prices, Long-term Supply and Demand Dynamics Remain Uncertain
-
Ethyl Acetate Prices Continue to Decline
-
MIBK Market in 2025 Stabilizes First, Then Declines; Enters Supply and Demand Optimization Stage in 2026
-
Acetic Acid Market Trends Consolidate (May 18–May 24)